BioCentury | Jan 13, 2003
Clinical News

Moli1901 duramycin regulatory update

...designation for MLCM's Moli1901 to treat cystic fibrosis. The product is in Phase II testing. MoliChem Medicines Inc....
BioCentury | Jan 6, 2003
Finance

Restructuring watch

...back to 2,450 in 2003 by adding workers in later-stage development. $1,800.0 4.6 $292.0 12/27 MoliChem...
BioCentury | Jan 6, 2003
Company News

InterMune, MoliChem deal

...eight to focus on partnering its pipeline compounds, including Moli1901. InterMune Inc. (ITMN), Brisbane, Calif. MoliChem Medicines Inc....
BioCentury | Dec 27, 2002
Company News

InterMune, MoliChem terminate CF deal

ITMN and MLCM terminated their 2001 a development and commercialization deal for MLCM's Moli1901 to treat cystic fibrosis (CF). As a result, MLCM reacquired all rights to the compound and will not receive and future...
BioCentury | Jun 3, 2002
Clinical News

Moli1901 duramycin: MLCM began a U.S. Phase II trial of Moli1901 in CF patients. The company said the trial will assess the delivery and deposition of the compo

MoliChem Medicines Inc. (MLCM), Chapel Hill, N.C. Product: Moli1901 duramycin (2622U90) Business: Pulmonary Therapeutic category: Ion channel modulation Target: Chloride channels Description: Pulmonary delivery of polycyclic peptide antibiotic that induces chloride and water transport in...
BioCentury | May 29, 2002
Clinical News

MoliChem starts CF Phase II

MLCM began a U.S. Phase II trial of Moli1901 to treat cystic fibrosis (CF). The compound is a polycyclic peptide antibiotic delivered through the lungs and induces chloride and water transport in airway cells. The...
BioCentury | Apr 15, 2002
Clinical News

Moli1901 duramycin: Phase Ib

...was well tolerated at doses ?2.5 mg, with no adverse events or significant airway irritation. MoliChem Medicines Inc....
BioCentury | Mar 11, 2002
Clinical News

Moli56B ferrioxamine B regulatory update

...covering the use of Moli56B to treat septic shock. The product is in preclinical testing. MoliChem Medicines Inc....
BioCentury | May 14, 2001
Company News

InterMune, MoliChem deal

...testing for CF in the second half of the year. InterMune Inc. (ITMN), Burlingame, Calif. MoliChem Medicines Inc....
BioCentury | May 11, 2001
Company News

InterMune, MoliChem in pulmonary deal

The companies will jointly develop and market MLCM's Moli1901 duramycin pulmonary compound worldwide. MLCM will receive a $1.5 million upfront payment plus milestones. ITMN and MLCM will share equally in the expenses and profits. Moli1901,...
Items per page:
1 - 10 of 14
BioCentury | Jan 13, 2003
Clinical News

Moli1901 duramycin regulatory update

...designation for MLCM's Moli1901 to treat cystic fibrosis. The product is in Phase II testing. MoliChem Medicines Inc....
BioCentury | Jan 6, 2003
Finance

Restructuring watch

...back to 2,450 in 2003 by adding workers in later-stage development. $1,800.0 4.6 $292.0 12/27 MoliChem...
BioCentury | Jan 6, 2003
Company News

InterMune, MoliChem deal

...eight to focus on partnering its pipeline compounds, including Moli1901. InterMune Inc. (ITMN), Brisbane, Calif. MoliChem Medicines Inc....
BioCentury | Dec 27, 2002
Company News

InterMune, MoliChem terminate CF deal

ITMN and MLCM terminated their 2001 a development and commercialization deal for MLCM's Moli1901 to treat cystic fibrosis (CF). As a result, MLCM reacquired all rights to the compound and will not receive and future...
BioCentury | Jun 3, 2002
Clinical News

Moli1901 duramycin: MLCM began a U.S. Phase II trial of Moli1901 in CF patients. The company said the trial will assess the delivery and deposition of the compo

MoliChem Medicines Inc. (MLCM), Chapel Hill, N.C. Product: Moli1901 duramycin (2622U90) Business: Pulmonary Therapeutic category: Ion channel modulation Target: Chloride channels Description: Pulmonary delivery of polycyclic peptide antibiotic that induces chloride and water transport in...
BioCentury | May 29, 2002
Clinical News

MoliChem starts CF Phase II

MLCM began a U.S. Phase II trial of Moli1901 to treat cystic fibrosis (CF). The compound is a polycyclic peptide antibiotic delivered through the lungs and induces chloride and water transport in airway cells. The...
BioCentury | Apr 15, 2002
Clinical News

Moli1901 duramycin: Phase Ib

...was well tolerated at doses ?2.5 mg, with no adverse events or significant airway irritation. MoliChem Medicines Inc....
BioCentury | Mar 11, 2002
Clinical News

Moli56B ferrioxamine B regulatory update

...covering the use of Moli56B to treat septic shock. The product is in preclinical testing. MoliChem Medicines Inc....
BioCentury | May 14, 2001
Company News

InterMune, MoliChem deal

...testing for CF in the second half of the year. InterMune Inc. (ITMN), Burlingame, Calif. MoliChem Medicines Inc....
BioCentury | May 11, 2001
Company News

InterMune, MoliChem in pulmonary deal

The companies will jointly develop and market MLCM's Moli1901 duramycin pulmonary compound worldwide. MLCM will receive a $1.5 million upfront payment plus milestones. ITMN and MLCM will share equally in the expenses and profits. Moli1901,...
Items per page:
1 - 10 of 14